Non-Small Cell Lung Cancer (NSCLC) – Current and Future Players

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2995

GlobalData has released its pharma report, “Non-Small Cell Lung Cancer (NSCLC) – Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing NSCLC Market. The report identifies and analyses the key companies shaping and driving the global NSCLC market. The report provides insight into the competitive NSCLC landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData’s team of industry experts. *This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase.

Scope

Investigation of current and future market competition for NSCLC

Competitor assessment

Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.

Strategic assessment of NSCLC sector through market impact analysis, future market scenario and company analysis

Reasons to Buy

Gain a high level view of the trends shaping and driving NSCLC market

Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.

Create an effective counter-strategy to gain a competitive advantage against those currently in the market

What’s the next big thing in the global NSCLC market landscape? Identify, understand and capitalize

Table of Contents

1Table of Contents

1.1List of Tables

1.2List of Figures

2Introduction

2.1Catalyst

2.2Related Reports

2.3Upcoming Related Reports

3Market Outlook

3.1Global Markets

3.1.1Forecast

3.1.2Drivers and Barriers – Global Issues

4Current and Future Players

4.1Overview

4.2Trends in Corporate Strategy

4.3Company Profiles

4.3.1Roche/Genentech

4.3.2Eli Lilly

4.3.3Pfizer

4.3.4AstraZeneca

4.3.5Bristol-Myers Squibb

4.3.6Merck & Co.

4.3.7Novartis

4.3.8Boehringer Ingelheim

5Appendix

5.1Bibliography

5.2Abbreviations

5.3Methodology

5.4Forecasting Methodology

5.4.1Diagnosed NSCLC Patients

5.4.2Percent Drug-Treated Patients

5.4.3Drugs Included in Each Therapeutic Class

5.4.4Launch and Patent Expiry Dates

5.4.5General Pricing Assumptions

5.4.6Individual Drug Assumptions

5.4.7Generic Erosion

5.4.8Pricing of Pipeline Agents

5.5Primary Research – KOLs

5.5.1KOLs

5.6About the Authors

5.6.1Analyst

5.6.2Therapy Area Director

5.6.3Epidemiologist

5.6.4Global Head of Healthcare

5.7About GlobalData

5.8Disclaimer

Table

Table 1: NSCLC – Global Drivers and Barriers, 2015?2025

Table 2: Key Companies in the NSCLC Market in the 8MM, 2015–2025

Table 3: Roche/Genentech’s NSCLC Portfolio Assessment, 2016

Table 4: Eli Lilly’s NSCLC Portfolio Assessment, 2016

Table 5: Pfizer’s NSCLC Portfolio Assessment, 2016

Table 6: AZ’s NSCLC Portfolio Assessment, 2016

Table 7: BMS’ NSCLC Portfolio Assessment, 2016

Table 8: Merck & Co.’s NSCLC Portfolio Assessment, 2016

Table 9: Novartis’ NSCLC Portfolio Assessment, 2016

Table 10: BI’s NSCLC Portfolio Assessment, 2016

Table 11: Key Launch Dates – Part I

Table 12: Key Launch Dates – Part II

Table 13: Key Patent Expiries

Table 14 Average Body Weight and Surface Area Across the 8MM

Table 15: Average Cost of Therapy of Alimta in the 8MM

Table 16: Average Cost of Therapy of Alecensa in the 8MM

Table 17: Average Cost of Therapy of Avastin

Table 18: Average Cost of Therapy of Cyramza

Table 19: Average Cost of Therapy of Gilotrif

Table 20: Average Cost of Therapy of Iressa

Table 21: Average Cost of Therapy of Portrazza

Table 22: Average Cost of Therapy of Tagrisso

Table 23: Average Cost of Therapy of Tarceva

Table 24: Average Cost of Therapy of Vargatef

Table 25: Average Cost of Therapy of Xalkori

Table 26: Average Cost of Therapy of Zykadia

Table 27: Average Cost of Therapy of Keytruda

Table 28: Average Cost of Therapy of Opdivo

Table 29: Average Cost of Therapy of Tecentriq

Table 30: Average Cost of Therapy of Conmana

Table 31: High-Prescribing Physicians Surveyed by Country

Figures

Figure 1: Global Sales for NSCLC (8MM), 2015–2025

Figure 2: Global Sales for NSCLC (8MM), 2015–2025

Figure 3: Global Sales for NSCLC (8MM), 2015–2025

Figure 4: Global Sales of Branded Products for NSCLC by Company, 2015–2025

Figure 5: Company Portfolio Gap Analysis in NSCLC, 2015–2025

Figure 6: Roche/Genentech SWOT Analysis in NSCLC, 2016

Figure 7: Eli Lilly SWOT Analysis in NSCLC, 2016

Figure 8: Pfizer SWOT Analysis in NSCLC, 2016

Figure 9: AZ SWOT Analysis in NSCLC, 2016

Figure 10: BMS SWOT Analysis in NSCLC, 2016

Figure 11: Merck & Co. SWOT Analysis in NSCLC, 2016

Figure 12: Novartis SWOT Analysis in NSCLC, 2016

Figure 13: BI SWOT Analysis in NSCLC, 2016

Frequently asked questions

Non-Small Cell Lung Cancer (NSCLC) – Current and Future Players standard reports
Currency USD
$2,995

Can be used by individual purchaser only

$8,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Non-Small Cell Lung Cancer (NSCLC) – Current and Future Players in real time.

  • Access a live Non-Small Cell Lung Cancer (NSCLC) – Current and Future Players dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.